Offering lifelong antiretroviral therapy to all HIV-infected pregnant and breastfeeding women to prevent mother-to-child transmission has resulted in a huge increase in ART initiations among such women.
Substantial progress has been made in reducing the rates of mother-to-child transmission of HIV worldwide. However, HIV-infected pregnant women in low- and middle-income countries do not always receive antiretroviral therapy (ART) to prevent such transmission, as well as to treat their own HIV disease. One of the main barriers has been inadequate access to CD4 cell–count testing to determine when ART should be initiated.
In Malawi, given the limited capacity to determine CD4-cell counts, the Ministry of Health implemented “Option B+,” which provides lifelong ART to all HIV-infected pregnant and breastfeeding women, regardless of CD4-cell count. In preparation for this implementation, 4839 healthcare workers were trained to initiate ART at Ma…
Reviewing Author
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes